Structure-based Design Targeted at LOX-1, a Receptor for Oxidized Low-Density Lipoprotein

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Thakkar, Shraddha ^a   Wang, Xianwei ^a   Khaidakov, Magomed ^a   Dai, Yao ^a   Gokulan, Kuppan ^a   Mehta, Jawahar L ^a   Varughese, Kottayil I ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MOLECULAR LIBRARY; OLR1 PROTEIN, HUMAN; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PROTEIN BINDING; VASCULAR CELL ADHESION MOLECULE 1;

ANTAGONISTS AND INHIBITORS; CELL ADHESION; CHEMISTRY; COMPUTER SIMULATION; CONFORMATION; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECTS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOLECULAR LIBRARY; MOLECULAR MODEL; PROTEIN DOMAIN; PROTEIN STABILITY; STRUCTURE ACTIVITY RELATION; UMBILICAL VEIN ENDOTHELIAL CELL;

CELL ADHESION; COMPUTER SIMULATION; DRUG DESIGN; DRUG DISCOVERY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIGANDS; LIPOPROTEINS, LDL; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STABILITY; SCAVENGER RECEPTORS, CLASS E; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84947593294     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16740     Document Type: Article

References (38)

1. Lu, J., Mitra, S., Wang, X., Khaidakov, M., Mehta, J. L. Oxidative stress and lectin-like ox-LDL-receptor LOX-1 in atherogenesis and tumorigenesis. Antioxid. Redox. Signal. 15, 2301-2333 (2011).
2. Mehta, J. L., Li, D. Y. Identification and autoregulation of receptor for OX-LDL in cultured human coronary artery endothelial cells. Biochem Biophys. Res Commun 248, 511-514 (1998).
3. Mehta, J. L. et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ. Res. 100, 1634-1642 (2007).
4. Wang, X., Phillips, M. I., Mehta, J. L. LOX-1 and angiotensin receptors, and their interplay. Cardiovasc Drugs Ther 25, 401-417 (2011).
5. Li, D. et al. LOX-1 inhibition in myocardial ischemia-reperfusion injury: modulation of MMP-1 and inflammation. Am. J. Physiol Heart Circ. Physiol 283, H1795-H1801 (2002).
6. Kataoka, K. et al. LOX-1 pathway affects the extent of myocardial ischemia-reperfusion injury. Biochem Biophys. Res Commun 300, 656-660 (2003).
7. Wang, X. et al. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) and cardiac fibroblast growth. Hypertension 60, 1437-1442 (2012).
8. Dandapat, A., Hu, C., Sun, L., Mehta, J. L. Small concentrations of oxLDL induce capillary tube formation from endothelial cells via LOX-1-dependent redox-sensitive pathway. Arterioscler. Thromb. Vasc. Biol. 27, 2435-2442 (2007).
9. Mehta, J. L. et al. LOX-1: a new target for therapy for cardiovascular diseases. Cardiovasc. Drugs Ther. 25, 495-500 (2011).
10. Chen, M., Narumiya, S., Masaki, T., Sawamura, T. Conserved C-terminal residues within the lectin-like domain of LOX-1 are essential for oxidized low-density-lipoprotein binding. Biochem. J. 355, 289-296 (2001).
11. Xie, Q. et al. Human lectin-like oxidized low-density lipoprotein receptor-1 functions as a dimer in living cells. DNA Cell Biol. 23, 111-117 (2004).
12. Park, H., Adsit, F. G., Boyington, J. C. The 1.4 angstrom crystal structure of the human oxidized low density lipoprotein receptor lox-1. J. Biol. Chem. 280, 13593-13599 (2005).
13. Ohki, I. et al. Crystal structure of human lectin-like, oxidized low-density lipoprotein receptor 1 ligand binding domain and its ligand recognition mode to OxLDL. Structure. 13, 905-917 (2005).
14. Segrest, J. P., Jones, M. K., De, L. H., Dashti, N. Structure of apolipoprotein B-100 in low density lipoproteins. J Lipid Res 42, 1346-1367 (2001).
15. S.Tate Structure and mode of ligand recognition of the oxidized LDL receptor, LOX-1. in Functional and Structural Biology on the Lipo-network, Transworld Research Network (ed. K. Morikawa & S.Tate) 179-198 (2006).
16. Francone, O. L. et al. The hydrophobic tunnel present in LOX-1 is essential for oxidized LDL recognition and binding. J. Lipid Res. 50, 546-555 (2009).
17. Falconi, M. et al. Design of a novel LOX-1 receptor antagonist mimicking the natural substrate. Biochem Biophys. Res Commun 438, 340-345 (2013).
18. Yoshiizumi, K., Nakajima, F., Dobashi, R., Nishimura, N., Ikeda, S. Studies on scavenger receptor inhibitors. Part 1: synthesis and structure-activity relationships of novel derivatives of sulfatides. Bioorg. Med Chem. 10, 2445-2460 (2002).
19. Yoshiizumi, K., Nakajima, F., Dobashi, R., Nishimura, N., Ikeda, S. 2,4-Bis(octadecanoylamino)benzenesulfonic acid sodium salt as a novel scavenger receptor inhibitor with low molecular weight. Bioorg. Med Chem. Lett. 14, 2791-2795 (2004).
20. Nishizuka, T. et al. Procyanidins are potent inhibitors of LOX-1: a new player in the French Paradox. Proc Jpn. Acad Ser. B Phys Biol Sci 87, 104-113 (2011).
21. Biocca, S. et al. Molecular mechanism of statin-mediated LOX-1 inhibition. Cell Cycle 14, 1583-1595 (2015).
22. Kostner, G. M. et al. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 80, 1313-1319 (1989).
23. Irwin, J. J., Sterling, T., Mysinger, M. M., Bolstad, E. S., Coleman, R. G. ZINC: A Free Tool to Discover Chemistry for Biology. J. Chem Inf Model 52, 1757-1768 (2012).
24. SYBYL-X 2.0. Tripos International, 1699 South Hanley Rd., St.Louis, Missouri, 63144, USA. Tripos International, 1699 South Hanley Rd., St.Louis, Missouri, 63144, USA. 2012.
25. Niesen, F. H., Berglund, H., Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2, 2212-2221 (2007).
26. Sakamoto, N. et al. Role of LOX-1 in monocyte adhesion-triggered redox, Akt/eNOS and Ca2+ signaling pathways in endothelial cells. J Cell Physiol 220, 706-715 (2009).
27. Ding, Z. et al. Concentration polarization of ox-LDL activates autophagy and apoptosis via regulating LOX-1 expression. Sci Rep 3, 2091 (2013).
28. Libby, P. Inflammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 32, 2045-2051 (2012).
29. Libby, P. Inflammation in atherosclerosis. Nature 420, 868-874 (2002).
30. Khaidakov, M. et al. Large Impact of Low Concentration Oxidized LDL on Angiogenic Potential of Human Endothelial Cells: A Microarray Study. PLoS. ONE. 7, e47421 (2012).
31. Silvestre, H. L., Blundell, T. L., Abell, C., Ciulli, A. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery. Proc Natl Acad Sci USA 110, 12984-12989 (2013).
32. Iwamoto, S. et al. Generation and characterization of chicken monoclonal antibodies against human LOX-1. MAbs. 1, 357-363 (2009).
33. Sethu, S. et al. Immunogenicity to biologics: mechanisms, prediction and reduction. Arch Immunol Ther Exp (Warsz. ) 60, 331-344 (2012).
34. Mehta, J. L., Chen, J., Yu, F., Li, D. Y. Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells. Cardiovasc Res 64, 243-249 (2004).
35. Lipinski, C. A., Lombardo, F., Dominy, B. W., Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv. Rev 46, 3-26 (2001).
36. Smith, G. F. Designing drugs to avoid toxicity. Prog Med Chem. 50, 1-47 (2011).
37. Sekhar, P. N. et al. In silico modeling and hydrogen peroxide binding study of rice catalase. In Silico. Biol 6, 435-447 (2006).
38. Jain, A. N. Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J Comput Aided Mol Des 21, 281-306 (2007).